Tanacetum parthenium, also known as feverfew plant, grows widely across Europe and North America. The leaves of Tanacetum parthenium have been historically used for the therapy of fever and more recently migraine headaches. For centuries, healers relied on the feathery green leaves of Tanacetum parthenium herb to treat headaches, stomach upset, rheumatoid arthritis, and menstrual problems. The bright yellow and white blossoms of this flower emit a powerful aroma that was once thought to purify the air and prevent disease. This herb has also long been used in gardens to repel bees and various insects. And as its common name suggests, it was once popular for reducing fever. This herb was somewhat forgotten, however, until the late 1970s. That's when migraine sufferers started talking about the potential of Tanacetum parthenium herb to ward off headaches.
Feverfew supplement, 30 Capsules - Enzymatic Therapy
Tanacetum parthenium herb is stabilized and standardized to guarantee 600 mcg of parthenolide per capsule. Parthenolide is Tanacetum parthenium 's most medically useful compound. Tanacetum parthenium supplement is made from Tanacetum parthenium flowers and leaves harvested when the plant is richest in parthenolide content. Just one or two Tanacetum parthenium extract capsule daily provides the benefit Tanacetum parthenium herb has to offer.
Recommendations: One to three capsules daily. Best results are obtained with consistent use.
Click here to buy Tanacetum parthenium supplement
Feverfew supplement facts:
Servings Size 1 capsule
Tanacetum parthenium extract - 100 mg Flower and leaf standardized to contain 600 mcg of parthenolide
Tanacetum parthenium extract dosage
The routine dosage is 100 to 300 mg up to three times a day. Tanacetum parthenium extract is sold by herb and raw ingredient suppliers as 0.2 percent parthenolide, to 0.4 percent parthenolide, 0.5 percent parthenolide and 0.6 percent parthenolide..
Tanacetum parthenium side effects
Since Tanacetum parthenium extract may potentially thin the blood, caution should be taken if you are on coumadin, aspirin, or blood thinners. No major Tanacetum parthenium side effects have been reported in the medical literature as of January 2008.
Tanacetum parthenium extract summary
Results of studies with Tanacetum parthenium extract in the therapy or prevention of migraine headaches have not been consistent. It appears that a small percentage of users may benefit from Tanacetum parthenium , but a good portion of users may not find this herb helpful.
The Tanacetum parthenium extract dosage is about 100 to 150 mg of the freeze-dried powdered herb, containing at least 0.4% parthenolide, taken twice a day. Benefits may be noticed within a month or two. Exercise, B vitamins, and magnesium supplements may also help. Some migraine sufferers also notice benefits from a low gluten diet.
Anti-inflammatory activity of parthenolide-depleted Feverfew Tanacetum parthenium.
Inflammopharmacology. 2009; Sur R, Martin K, Liebel F, Lyte P, Shapiro S, Southall M. Preclinical Pharmacology, Johnson and Johnson Skin Research Center, CPPW, a unit of Johnson & Johnson Consumer Companies, Inc., Skillman, NJ, USA.
Extracts of Tanacetum parthenium (L.) Sch. Bip.,contains the sesquiterpene lactone parthenolide, a potent skin sensitizer. To eliminate the risk of skin sensitization from Feverfew, we developed a parthenolide-depleted extract of Feverfew and determined its effectiveness as an anti-inflammatory agent. Our results indicate that parthenolide-depleted extract of Feverfew has potent anti-inflammatory activity suggesting that this botanical would be efficacious in relieving inflammation without inducing immune sensitization.
Tanacetum parthenium migraine
Efficacy and safety of 6.25 mg t.i.d. Tanacetum parthenium extract MIG-99 in migraine prevention--a randomized, double-blind, multicentre, placebo-controlled study.
The efficacy and tolerability of a CO(2)-extract of Tanacetum parthenium (MIG-99, 6.25 mg t.i.d.) for migraine prevention were investigated in a randomized, double-blind, placebo-controlled, multicentre, parallel-group study. Patients (N = 170 intention-to-treat; MIG-99, N = 89; placebo, N = 81) suffering from migraine according to International Headache Society criteria were treated for 16 weeks after a 4-week baseline period. The primary endpoint was the average number of migraine attacks per 28 days during the treatment months 2 and 3 compared with baseline. Safety parameters included adverse events, laboratory parameters, vital signs and physical examination. The migraine frequency decreased from 4.76 by 1.9 attacks per month in the MIG-99 group and by 1.3 attacks in the placebo group. Logistic regression of responder rates showed an odds ratio of 3.4 in favour of Tanacetum parthenium . Adverse events possibly related to study medication were 9/107 (8%) with Tanacetum parthenium and 11/108 (10%) with placebo. Tanacetum parthenium is effective and shows a favourable benefit-risk ratio.
A stable extract of the popular herbal remedy Tanacetum parthenium, called MIG-99, appears to be particularly effective in preventing migraine, German researchers report in the November 2005 issue of Cephalagia. Tanacetum parthenium herb has traditionally been used to treat migraine, and clinical trials of the powdered herb have shown promising results. However, tests using extracts of Tanacetum parthenium have been less successful. To evaluate Tanacetum parthenium , the researchers conducted a trial with 170 migraine patients. At the beginning of the trial, migraine frequency was approximately five attacks over a 4-week period. The subjects were then randomly assigned to treatment with Tanacetum parthenium, three times a day or to placebo, or "sugar pill," for up to 16 weeks. In the Tanacetum parthenium treatment group, migraine frequency declined by two attacks per month. In the placebo patients, the corresponding decrease was only one per month. Possible medication-related adverse events occurred in about 8.4 percent of Tanacetum parthenium patients and 10.2 percent of placebo patients. Further analysis of responder rates revealed that Tanacetum parthenium was 3.4-times more effective than placebo.
Tanacetum parthenium for preventing migraine.
Cochrane Database Syst Rev. 2004. Department of Complementary Medicine, Peninsula Medical School, Universities of Exeter and Plymouth, Exeter, Devon, UK.
Tanacetum parthenium extract is a herbal remedy used for preventing attacks of migraine. To systematically review the evidence from double-blind randomised controlled trials assessing the clinical efficacy and safety of Tanacetum parthenium versus placebo for preventing migraine. Trials using clinical outcome measures were included. Trials focusing exclusively on physiological parameters were excluded. There were no restrictions regarding the language of publication. Data on patients, interventions, methods, outcome measures, results and adverse events were extracted systematically. Two reviewers independently selected studies, assessed methodological quality and extracted data. Disagreements concerning evaluation of individual trials were resolved through discussion. Five trials (343 patients) met the inclusion criteria. Results from these trials were mixed and did not convincingly establish that Tanacetum parthenium is efficacious for preventing migraine. Only mild and transient adverse events were reported in the included trials. There is insufficient evidence from randomised, double-blind trials to suggest an effect of Tanacetum parthenium over and above placebo for preventing migraine. It appears from the data reviewed that Tanacetum parthenium presents no major safety problems.
The efficacy and safety of Tanacetum parthenium in migraine
prophylaxis--a double-blind, multicentre, randomized placebo-controlled
Tanacetum parthenium herb has been used as a prevention for migraine headache. The primary objective was to show a dose-response of a new stable extract (MIG-99) reproducibly manufactured with supercritical CO2 from Tanacetum parthenium herb. Furthermore, the study should provide data on the safety and tolerability of MIG-99. In a randomized, double-blind, multicentre, controlled trial with an adaptive design, the clinical efficacy and safety of three dosages of MIG-99 (2.08 mg; 6.25 mg; 18.75 mg t.i.d.) were compared with placebo. The patients suffered from migraine with and without aura according to International Headache Society (IHS) criteria and were treated with one of the study medications for 12 weeks after a 4-week baseline period. The primary efficacy parameter was the number of migraine attacks during the last 28 days of the treatment period compared with baseline. Secondary endpoints were total and average duration and intensity of migraine attacks, mean duration of the single attack, number of days with accompanying migraine symptoms, number of days with inability to work due to migraine as well as type and amount of additionally taken medications for the treatment of migraine attacks. The design of the study included a pre-planned adaptive interim analysis for patients with at least four migraine attacks within the baseline period. With respect to the primary and secondary efficacy parameter, a statistically significant difference was not found between the overall and the confirmatory intention-to-treat (ITT) sample in the exploratorily analysed four treatment groups. The frequency of migraine attacks for the predefined confirmatory subgroup of patients (n = 49) with at least four migraine attacks during the baseline period decreased in a dose-dependent manner. The highest absolute change of migraine attacks was observed under Tanacetum parthenium treatment with 6.25 mg t.i.d. compared with placebo. Overall, 52 of 147 (35%) patients reported at least one adverse event (AE). The incidence of AEs in the Tanacetum parthenium treatment groups was similar to that in the placebo group, and no dose-related effect was observed in any safety parameter. MIG-99 failed to show a significant migraine prophylactic effect in general. Accordingly, in the ITT analysis a dose-response relationship could not be observed. MIG-99 was shown to be effective only in a small predefined subgroup of patients with at least four attacks during the 28-day baseline period where the most favourable benefit-risk ratio was observed with a dosage of three capsules of 6.25 mg MIG-99 extract per day. Because of the low number of patients, these findings need to be verified in a larger sample. The incidence of AEs was similar for all treatment groups.
Tanacetum parthenium extract and
Parthenolide, a chemical derived from the Tanacetum parthenium plant, destroys acute myeloid leukemia (AML) cells, leaving normal bone marrow cells relatively unscathed. Moreover, the compound may get at the root of the disease because it also kills stem cells that give rise AML.
Tanacetum parthenium extract as anti-inflammatory
Tanacetum parthenium herb -- The Yale team found that Tanacetum parthenium's active ingredient -- parthenolide -- specifically binds to and inhibits the protein IKK-beta, which plays a role in the body's inflammatory process. Fever is part of the body's inflammatory response, and inflammation contributes to a range of ailments--including migraines. 100 to 300 mg up to qid, 0.2 to 0.4% parthenolide.
Effect on vascular cells
Parthenolide inhibits proliferation of vascular smooth muscle cells through induction of G0/G1 phase cell cycle arrest.
J Zhejiang Univ Sci B. 2009; Department of Cardiology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China. This study is to determine the effect of the natural product parthenolide, a sesquiterpene lactone isolated from extracts of the herb Tanacetum parthenium, on the proliferation of vascular smooth muscle cells (VSMCs). Rat aortic VSMCs were isolated and cultured in vitro, and treated with different concentrations of parthenolide (10, 20 and 30 mumol/L). [(3)H]thymidine incorporation was used as an index of cell proliferation. Cell cycle progression and distribution were determined by flow cytometric analysis. Our results show that parthenolide significantly inhibits the VSMC proliferation by inducing G(0)/G(1) cell cycle arrest. IkappaBalpha and Cox-2 are likely involved in such inhibitory effect of parthenolide on VSMC proliferation. These findings warrant further investigation on potential therapeutic implications of parthenolide on VSMC proliferation in vivo.
Q. Was just reading with interest your article on Tanacetum parthenium supplement. I have CML leukemia; a few of my friends are taking Tanacetum parthenium to supplement their Imatinib. In three distinct cases, they have had disease reversal when they seemed to be failing imatinib. Also, it may be important to note that parthenolide is fat soluble. So dissolving Tanacetum parthenium in a fat may make it even more bioavailable. I have just received my latest PCR results from my experimental use of Tanacetum parthenium and Curcumin together. My cancer load by PCR measure was cut from 1.812% to .821% Very substantial and this was on a four week cycle of the two natural compounds.
A. For readers who are not familiar, the polymerase chain reaction (PCR) is technique for exponentially amplifying DNA, via enzymatic replication, without using a living organism. What dosage of Tanacetum parthenium are you using?
Q. I am using about 6 grams of Tanacetum parthenium , dissolved in cream twice a day. 3 X 2. The product I am using is standardized to 0.7% parthenolide. I am taking a Jarrow band of curcumin 8 Grams per day also dissolved in cream.. Both parthenolide and curcumin are fat soluable. I am taking it with food if possible but frankly dissolved like this it does not bother my GI tract. I assume this has something to do with fats being dissolved in lymphatic system. I still take imatinib. So I think all three are working together rather nicely!
Q. What is your opinion on Tanacetum parthenium and migraine?
A. As with any herb or medicine, there are some people who notice a benefit while others don't. It may be worthwhile to give Tanacetum parthenium extract a chance for about 6 to 8 weeks to see if it helps relieve symptoms of migraine.
home theanine sleep information supplement side effects benefits